logo

Diane Wara, MD

Diane Wara, MD

Allergy & Immunology San Francisco, CA

Recalled Faculty/Academic Specialist, Pediatrics, UCSF School of Medicine

Office Address

Office Map
  • 400 Parnassus Ave
    San Francisco, CA 94143
    Phone: (415) 476-2491
    Fax: (415) 502-7540

Dr. Wara's Clinical Specialties & Interests

  • Allergy & Immunology: General Allergy & Immunology

Dr. Wara's Education & Medical Training

  • University of California at San FranciscoUniversity of California at San FranciscoResidency, Pediatrics
  • Los Angeles County-Harbor-UCLA Medical CenterLos Angeles County-Harbor-UCLA Medical CenterResidency, Pediatrics
  • UC, Irvine CA Coll of MedUniversity of California, Irvine School of MedicineMedical School

Dr. Wara's Certifications & Licensure

  • CA State Medical LicenseCA State Medical License1970 - 2014
  • American Board of Allergy and ImmunologyAmerican Board of Allergy and ImmunologyAllergy & Immunology
  • American Board of PediatricsAmerican Board of PediatricsPediatrics

Dr. Wara's Awards, Honors, & Recognition

  • Institute of MedicineElected MemberInstitute of Medicine, 1998
  • SuperDoctors.comSuper DoctorSuperDoctors.com

Dr. Wara's Publications & Presentations

PubMed | Citations by Web of Science®

Grant Support

  • Effects Of Haart On The Recovery Of Immune Function In Hiv-Infected Children
    Effects Of Haart On The Recovery Of Immune Function In Hiv-Infected ChildrenNational Center For Research Resources
    2005 - 2005
  • Pactg 1020-A, Version 20
    Pactg 1020-A, Version 20National Center For Research Resources
    2005 - 2005
  • Pediatric LATE Outcomes Protocol (Aids Clinical Trials Group: 219c)
    Pediatric LATE Outcomes Protocol (Aids Clinical Trials Group: 219c)National Center For Research Resources
    2005 - 2005
  • Pactg P1057: Phase I/II Randomized Trial Of Cold Adapted Influenza Vaccine
    Pactg P1057: Phase I/II Randomized Trial Of Cold Adapted Influenza VaccineNational Center For Research Resources
    2005 - 2005
  • Pactg P1045: Morphologic And Metabolic Abnormalities In Children &Youth
    Pactg P1045: Morphologic And Metabolic Abnormalities In Children &YouthNational Center For Research Resources
    2005 - 2005
  • Pactg P1042s: Cognitive, Behavioral And Psychosocial Correlates
    Pactg P1042s: Cognitive, Behavioral And Psychosocial CorrelatesNational Center For Research Resources
    2005 - 2005
  • Pactg P1025: Perinatal Core Protocol For Data From Hiv-Infected Pregnant Women
    Pactg P1025: Perinatal Core Protocol For Data From Hiv-Infected Pregnant WomenNational Center For Research Resources
    2004 - 2005
  • Pactg P1026s:Pharmacokinetic Properties Of Antiretroviral Drugs During Pregnancy
    Pactg P1026s:Pharmacokinetic Properties Of Antiretroviral Drugs During PregnancyNational Center For Research Resources
    2004 - 2005
  • Pactg P1030: Phase I/II Study Of Lopinavir/Ritonavir In HIV-1 Infected Infants
    Pactg P1030: Phase I/II Study Of Lopinavir/Ritonavir In HIV-1 Infected InfantsNational Center For Research Resources
    2004 - 2005
  • Pactg 1020-A, Version 2.0
    Pactg 1020-A, Version 2.0National Center For Research Resources
    2004 - 2004
  • Phase I/II Study Of Alvac HIV Vaccine In Children
    Phase I/II Study Of Alvac HIV Vaccine In ChildrenNational Center For Research Resources
    2004 - 2005
  • Immunological And Neurodevelopmental Consequences Of Chromosome 22q11.2 Deletion
    Immunological And Neurodevelopmental Consequences Of Chromosome 22q11.2 DeletionNational Center For Research Resources
    2004 - 2004
  • Defective T- And B- Cell Signaling In Patients With Inherited Immunodeficiencies
    Defective T- And B- Cell Signaling In Patients With Inherited ImmunodeficienciesNational Center For Research Resources
    2004 - 2005
  • Clinical And Molecular Investigation Of Primary Immunodeficiencies
    Clinical And Molecular Investigation Of Primary ImmunodeficienciesNational Center For Research Resources
    2004 - 2005
  • Phase I/II Trial Of Subcutaneous IL-2 With Antiretroviral Therapy In HIV
    Phase I/II Trial Of Subcutaneous IL-2 With Antiretroviral Therapy In HIVNational Center For Research Resources
    2004 - 2004
  • Pediatric LATE Outcomes Protocol (Actg 219c)
    Pediatric LATE Outcomes Protocol (Actg 219c)National Center For Research Resources
    2004 - 2004
  • Pactg P1021: Emtricitabine With Efavirenz And Didanosine In A Once Daily Regimen
    Pactg P1021: Emtricitabine With Efavirenz And Didanosine In A Once Daily RegimenNational Center For Research Resources
    2004 - 2004
  • Pactg P1024: Evaluation Of Pneumococcal Vaccine In Hiv-Infected Children
    Pactg P1024: Evaluation Of Pneumococcal Vaccine In Hiv-Infected ChildrenNational Center For Research Resources
    2004 - 2005
  • Northern California Pediatrics AIDS Treatment Center
    Northern California Pediatrics AIDS Treatment CenterNational Institute Of Allergy And Infectious Diseases
    2002 - 2006
  • ACTG 351: CD4 Igg2 In HIV Infected Children
    ACTG 351: CD4 Igg2 In HIV Infected ChildrenNational Center For Research Resources
    2000 - 2002
  • ACTG 366: Antiretroviral Algorithm For Children Of 4 Drug Combination
    ACTG 366: Antiretroviral Algorithm For Children Of 4 Drug CombinationNational Center For Research Resources
    2000 - 2002
  • Quantifying HIV 1 RNA In CSF &Blood Of HIV Infected Children
    Quantifying HIV 1 RNA In CSF &Blood Of HIV Infected ChildrenNational Center For Research Resources
    2000 - 2002
  • ACTG 395: Indinavir W/ Stavudine &Lamivudine For Pediatric HIV 1 Inf
    ACTG 395: Indinavir W/ Stavudine &Lamivudine For Pediatric HIV 1 InfNational Center For Research Resources
    2000 - 2002
  • Opportunistic Infection Events In HIV Infected Children
    Opportunistic Infection Events In HIV Infected ChildrenNational Center For Research Resources
    2000 - 2000
  • Correlation Of Growth With HIV Viral Load In Children
    Correlation Of Growth With HIV Viral Load In ChildrenNational Center For Research Resources
    2000 - 2000
  • Saquinavir Combination Therapy For HIV Children
    Saquinavir Combination Therapy For HIV ChildrenNational Center For Research Resources
    2000 - 2000
  • ACTG 377: Pram 2 Comparing 4 Antiretroviral Regimens
    ACTG 377: Pram 2 Comparing 4 Antiretroviral RegimensNational Center For Research Resources
    2000 - 2002
  • ACTG 316: Nevirapine VS Placebo For Preventing Maternal Fetal Transmission
    ACTG 316: Nevirapine VS Placebo For Preventing Maternal Fetal TransmissionNational Center For Research Resources
    1999 - 2002
  • Actg250--Safety/Pks Of Nevirapine In HIV1 Infected Pregnant Women/Neonates
    Actg250--Safety/Pks Of Nevirapine In HIV1 Infected Pregnant Women/NeonatesNational Center For Research Resources
    1998 - 1999
  • Impact Of Diagnostic Disclosure On HIV Infected Children
    Impact Of Diagnostic Disclosure On HIV Infected ChildrenNational Center For Research Resources
    1998 - 2002
  • Nevirapine VS Placebo To Prevent Maternal-Fetal HIV Transmission
    Nevirapine VS Placebo To Prevent Maternal-Fetal HIV TransmissionNational Center For Research Resources
    1998 - 2002
  • Safety And Immunogenicity Of Recombinant HIV 1
    Safety And Immunogenicity Of Recombinant HIV 1National Center For Research Resources
    1998 - 1999
  • Phase II Rolling Arm Master Protocol Of Novel Antiretroviral Therapy In HIV
    Phase II Rolling Arm Master Protocol Of Novel Antiretroviral Therapy In HIVNational Center For Research Resources
    1998 - 2002
  • Phase I/II Trial Of Recombinant IL 2 In Symptomatic HIV Infected Children
    Phase I/II Trial Of Recombinant IL 2 In Symptomatic HIV Infected ChildrenNational Center For Research Resources
    1998 - 2002
  • Atovaquone In HIV Infected Infants And Children
    Atovaquone In HIV Infected Infants And ChildrenNational Center For Research Resources
    1998 - 2002
  • Atovaquone And AZT Versus Tmp In HIV Infected Children
    Atovaquone And AZT Versus Tmp In HIV Infected ChildrenNational Center For Research Resources
    1998 - 2002
  • Phase I/II Study Of Hivig In Slowing Progress Of Disease In HIV Infected Child
    Phase I/II Study Of Hivig In Slowing Progress Of Disease In HIV Infected ChildNational Center For Research Resources
    1997 - 1999
  • Hyperimmune Anti HIV Immunoglobulin For Preventing Maternal/Fetal Transmission
    Hyperimmune Anti HIV Immunoglobulin For Preventing Maternal/Fetal TransmissionNational Center For Research Resources
    1997 - 1999
  • Atovaquone And AZT Versus Tmp In  HIV Infected Children
    Atovaquone And AZT Versus Tmp In HIV Infected ChildrenNational Center For Research Resources
    1997 - 1997
  • Single Dose PK And Safety Of Oral Adefovir Dipivoxil In HIV Infected Children
    Single Dose PK And Safety Of Oral Adefovir Dipivoxil In HIV Infected ChildrenNational Center For Research Resources
    1997 - 1999
  • Phase I Evaluation Of Safety/Toxicity Of ZDV And DDI Combination Therapy
    Phase I Evaluation Of Safety/Toxicity Of ZDV And DDI Combination TherapyNational Center For Research Resources
    1997 - 2002
  • Safety/Pharmacokinetics Of Nevirapine In HIV Infected Pregnant Women/Neonates
    Safety/Pharmacokinetics Of Nevirapine In HIV Infected Pregnant Women/NeonatesNational Center For Research Resources
    1996 - 1996
  • Trial Of DDC In Treatment Of Children With Symptomatic HIV Infection
    Trial Of DDC In Treatment Of Children With Symptomatic HIV InfectionNational Center For Research Resources
    1996 - 1996
  • Actg--Pediatric HIV LATE Outcomes Protocol
    Actg--Pediatric HIV LATE Outcomes ProtocolNational Center For Research Resources
    1996 - 1996
  • Hyperimmune Anti-Hiv Immunoglobulin For Preventing Maternal/Fetal Transmission
    Hyperimmune Anti-Hiv Immunoglobulin For Preventing Maternal/Fetal TransmissionNational Center For Research Resources
    1996 - 1996
  • Combined Zdv-Lamivudine VS DDI VS Zdv-Ddi In HIV
    Combined Zdv-Lamivudine VS DDI VS Zdv-Ddi In HIVNational Center For Research Resources
    1996 - 1999
  • Atovaquone &Azt Vs. Tmp In  HIV Infected Children
    Atovaquone &Azt Vs. Tmp In HIV Infected ChildrenNational Center For Research Resources
    1996 - 1996
  • Pk, Safety, Tolerance And Activity Of Ddc/Zdv In Pediatric Patients With HIV
    Pk, Safety, Tolerance And Activity Of Ddc/Zdv In Pediatric Patients With HIVNational Center For Research Resources
    1996 - 1996
  • Combination Antiretroviral Therapy In Children And Adolescents With Advanced HIV
    Combination Antiretroviral Therapy In Children And Adolescents With Advanced HIVNational Center For Research Resources
    1995 - 1999
  • Phase I Safety And PK Study Of Atovaquone In HIV Infected Infants And Children
    Phase I Safety And PK Study Of Atovaquone In HIV Infected Infants And ChildrenNational Center For Research Resources
    1995 - 1997
  • Treating SCID Due To ADA Deficiency With CD34+ Selected Autologous Stem Cells
    Treating SCID Due To ADA Deficiency With CD34+ Selected Autologous Stem CellsNational Center For Research Resources
    1995 - 2002
  • Randomized Comparative Trial Of ZDV VS D4T In Children With HIV Infection
    Randomized Comparative Trial Of ZDV VS D4T In Children With HIV InfectionNational Center For Research Resources
    1995 - 1997
  • Pediatric HIV LATE Outcomes Protocol
    Pediatric HIV LATE Outcomes ProtocolNational Center For Research Resources
    1995 - 2002
  • Clinical Investigation Of The Patient With Primary Immunodeficiency Disorder
    Clinical Investigation Of The Patient With Primary Immunodeficiency DisorderNational Center For Research Resources
    1995 - 2002
  • AZT VS DDI VS Azt/Ddi Combination In Symptomatic HIV Infected Children
    AZT VS DDI VS Azt/Ddi Combination In Symptomatic HIV Infected ChildrenNational Center For Research Resources
    1995 - 1999
  • High VS Low Dose Of DDI In Children With Symptomatic HIV Infection
    High VS Low Dose Of DDI In Children With Symptomatic HIV InfectionNational Center For Research Resources
    1995 - 1995
  • Three New HIV Vaccines In HIV Infected Children
    Three New HIV Vaccines In HIV Infected ChildrenNational Center For Research Resources
    1995 - 1999
  • HIV-1 Infected Pediatric Slow Or Rapid Progressors
    HIV-1 Infected Pediatric Slow Or Rapid ProgressorsNational Center For Research Resources
    1995 - 1995
  • Phase II Study To Evaluate Pk, Safety, Tolerance And Activity Of DDC
    Phase II Study To Evaluate Pk, Safety, Tolerance And Activity Of DDCNational Center For Research Resources
    1995 - 1995
  • Phase I Study--Safety And Immungenicity Of HIV-1 Recombinant Envelope Antigen
    Phase I Study--Safety And Immungenicity Of HIV-1 Recombinant Envelope AntigenNational Center For Research Resources
    1995 - 1995
  • Phase II Trial Of DDC In Treatment Of Children With Symptomatic HIV Infection
    Phase II Trial Of DDC In Treatment Of Children With Symptomatic HIV InfectionNational Center For Research Resources
    1995 - 1995
  • BAY Area Perinatal AIDS Cohort Study
    BAY Area Perinatal AIDS Cohort StudyEunice Kennedy Shriver National Institute Of Child Health &Human Development
    1992 - 1993
  • Northern California Pediatric AIDS Treatment Center
    Northern California Pediatric AIDS Treatment CenterNational Institute Of Allergy And Infectious Diseases
    1988 - 2001
  • Immunological Sciences Study Section
    Immunological Sciences Study SectionCenter For Scientific Review
    1987 - 1989
  • Safety Tolerance And OPEN Efficiency Of Rhcg Immune Serum Globulin
    Safety Tolerance And OPEN Efficiency Of Rhcg Immune Serum GlobulinNational Center For Research Resources
    1985 - 1985
  • Effects Of Thymosin On The Immune Function In Children
    Effects Of Thymosin On The Immune Function In ChildrenNational Center For Research Resources
    1985 - 1985

Hospital Affiliations

Alternate Names

  • Dr. Diane Wara, Dr. Diane Wara, MD, Dr. D Wara, Dr. Diane W. Wara

12 Colleague Invites!
Is this you? If so, register to see 12 messages.

Physicians, view Dr. Wara's full Doximity profile to:

  • Trade HIPAA-secure messages
  • Send and receive online faxes
  • Refer a patient
  • See their complete CV